New Oral Anticoagulants May Be Particularly Useful for Asian Stroke Patients.
- Author:
Oh Young BANG
1
;
Keun Sik HONG
;
Ji Hoe HEO
;
Jaseong KOO
;
Sun U KWON
;
Kyung Ho YU
;
Hee Joon BAE
;
Byung Chul LEE
;
Byung Woo YOON
;
Jong S KIM
Author Information
1. Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Publication Type:Review
- Keywords:
Atrial fibrillation;
Warfarin;
Stroke;
Intracranial hemorrhage;
Asians;
New oral anticoagulants
- MeSH:
Aging;
Anticoagulants*;
Asian Continental Ancestry Group*;
Atrial Fibrillation;
Delivery of Health Care;
Developed Countries;
Embolism;
Health Care Costs;
Hemorrhage;
Humans;
Insurance;
Intracranial Hemorrhages;
Population Characteristics;
Stroke*;
Warfarin
- From:Journal of Stroke
2014;16(2):73-80
- CountryRepublic of Korea
- Language:English
-
Abstract:
Atrial fibrillation (AF) is an emerging epidemic in both high-income and low-income countries, mainly because of global population aging. Stroke is a major complication of AF, and AF-related ischemic stroke is more disabling and more fatal than other types of ischemic stroke. However, because of concerns about bleeding complications, particularly intracranial hemorrhage, and the limitations of a narrow therapeutic window, warfarin is underused. Four large phase III randomized controlled trials in patients with non-valvular AF (RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE-AF-TIMI 48) demonstrated that new oral anticoagulants (NOACs) are superior or non-inferior to warfarin as regards their efficacy in preventing ischemic stroke and systemic embolism, and superior to warfarin in terms of intracranial hemorrhage. Among AF patients receiving warfarin, Asians compared to non-Asians are at higher risk of stroke or systemic embolism and are also more prone to develop major bleeding complications, including intracranial hemorrhage. The extra benefit offered by NOACs over warfarin appears to be greater in Asians than in non-Asians. In addition, Asians are less compliant, partly because of the frequent use of herbal remedies. Therefore, NOACs compared to warfarin may be safer and more useful in Asians than in non-Asians, especially in stroke patients. Although the use of NOACs in AF patients is rapidly increasing, guidelines for the insurance reimbursement of NOACs have not been resolved, partly because of insufficient understanding of the benefit of NOACs and partly because of cost concerns. The cost-effectiveness of NOACs has been well demonstrated in the healthcare settings of developed countries, and its magnitude would vary depending on population characteristics as well as treatment cost. Therefore, academic societies and regulatory authorities should work together to formulate a scientific healthcare policy that will effectively reduce the burden of AF-related stroke in this rapidly aging society.
